Want to see DMRA full AI Analyst Report?
DMRA Stock Chart & Stats
$29.00
$0.76(2.64%)
At close: 4:00 PM EDT
$29.00
$0.76(2.64%)
Day’s Range― - ―
52-Week Range$2.77 - $38.33
Previous CloseN/A
Volume313.81K
Average Volume (3M)413.53K
Market Cap
$1.41B
Enterprise Value$1.18K
Total Cash (Recent Filing)$540.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Oct 30, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-122.42
Shares Outstanding61,735,520
10 Day Avg. Volume641,804
30 Day Avg. Volume413,531
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.00Price Target Upside51.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal leverage reduces solvency and refinancing pressure while preserving financial flexibility for research, development, and other strategic priorities. A debt-light structure can help the company manage volatility as an early-stage biotech and avoid significant interest burdens while it remains pre-revenue.
Improved Cash BurnThe materially smaller cash outflow in 2025 indicates improved cash discipline compared with the prior year, even though cash generation remains negative. If sustained, lower burn could extend financial flexibility and reduce the pace at which external capital is required to fund operations.
Corporate ContinuityThe completed redomestication preserved the company’s operating business, management, contractual obligations, assets, liabilities, and Nasdaq listing. That continuity limits disruption from the structural change and provides a stable corporate framework while the company advances its longer-term development strategy.
Bears Say
No RevenueA continued absence of revenue means the company has not yet demonstrated commercial traction or an internally funded operating model. Until revenue emerges, financial performance will remain tied primarily to development progress and access to outside capital rather than recurring customer demand.
Sharp Loss ExpansionThe sharp increase in annual net loss highlights substantial and volatile spending relative to the company’s current operating base. Persistent losses reduce retained financial resources, make profitability difficult to forecast, and increase the importance of successful development and eventual commercialization.
Dependence On External FundingNegative operating and free cash flow across the reported periods means the business cannot currently fund its activities from operations. Continued dependence on external financing can constrain strategic flexibility and expose shareholders to future dilution or financing pressure if capital needs remain elevated.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics’s price range in the past 12 months?
Damora Therapeutics lowest stock price was $2.77 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics’s market cap?
Damora Therapeutics’s market cap is $1.41B.
When is Damora Therapeutics’s upcoming earnings report date?
Damora Therapeutics’s upcoming earnings report date is Oct 30, 2026 which is in 40 days.
How were Damora Therapeutics’s earnings last quarter?
Damora Therapeutics released its earnings results on Aug 10, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.024.
Is Damora Therapeutics overvalued?
According to Wall Street analysts Damora Therapeutics’s price is currently Undervalued.
Does Damora Therapeutics pay dividends?
Damora Therapeutics does not currently pay dividends.
What is Damora Therapeutics’s EPS estimate?
Damora Therapeutics’s EPS estimate is -0.48.
How many shares outstanding does Damora Therapeutics have?
Damora Therapeutics has 61,735,520 shares outstanding.
What happened to Damora Therapeutics’s price movement after its last earnings report?
Damora Therapeutics reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 2.776%.
Which hedge fund is a major shareholder of Damora Therapeutics?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (51.72% Upside)
$44.00 (51.72% Upside)
Blogger Sentiment
Bullish
DMRA Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 499.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
687.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3870.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Damora Therapeutics
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
DMRA Stock 12 Month Forecast
Average Price Target
$44.00
▲(51.72% Upside)
Technical Analysis
Iovance Biotherapeutics
―
AnaptysBio
―
Zymeworks
―
Stoke Therapeutics
―
Generate Biomedicines, Inc.
―
Ownership Overview
15.90% Insiders
10.69% Mutual Funds
― Other Institutional Investors
67.40% Public Companies and
Individual Investors